Insider Selling: CytomX Therapeutics, Inc. (CTMX) Insider Sells 13,052 Shares of Stock
CytomX Therapeutics, Inc. (NASDAQ:CTMX) insider Sean A. Mccarthy sold 13,052 shares of CytomX Therapeutics stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $21.04, for a total transaction of $274,614.08. Following the transaction, the insider now directly owns 17,695 shares of the company’s stock, valued at $372,302.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
CytomX Therapeutics, Inc. (NASDAQ CTMX) traded up $0.63 on Thursday, hitting $22.39. The stock had a trading volume of 240,900 shares, compared to its average volume of 266,100. CytomX Therapeutics, Inc. has a 12 month low of $10.64 and a 12 month high of $24.67. The firm has a market capitalization of $886.09 and a P/E ratio of -14.26.
A number of equities analysts have commented on CTMX shares. Wedbush started coverage on shares of CytomX Therapeutics in a research report on Thursday, September 7th. They set an “outperform” rating and a $26.00 price objective for the company. Nomura lifted their price objective on shares of CytomX Therapeutics to $44.00 and gave the stock a “buy” rating in a research report on Wednesday, October 4th. ValuEngine cut shares of CytomX Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. Zacks Investment Research downgraded CytomX Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 10th. Finally, BidaskClub downgraded CytomX Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, December 7th. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and eight have issued a buy rating to the company. CytomX Therapeutics currently has a consensus rating of “Hold” and an average price target of $31.88.
ILLEGAL ACTIVITY WARNING: “Insider Selling: CytomX Therapeutics, Inc. (CTMX) Insider Sells 13,052 Shares of Stock” was first published by Marea Informative and is owned by of Marea Informative. If you are accessing this news story on another site, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this news story can be viewed at https://www.mareainformativa.com/2018/01/04/insider-selling-cytomx-therapeutics-inc-ctmx-insider-sells-13052-shares-of-stock.html.
About CytomX Therapeutics
CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.
Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.